Phase I/II small-sample clinical trials indicate that DCVAC/PCa treatment demonstrates a favorable safety profile for prostate cancer and significantly prolongs the prostate-specific antigen doubling time [29,30]. Here, KLK3 is linked to prostate carcinoma.